Insmed Incorporated (INSM) FY2025 10-K Annual Report
Insmed Incorporated (INSM) 10-K annual report for fiscal year 2025, filed with SEC EDGAR on Feb 19, 2026. This page provides AI-powered analysis including business overview, management discussion & analysis (MD&A), risk factors, and key financial data such as revenue, net income, gross margin, operating margin, and return on equity (ROE) extracted from XBRL.
Insmed Incorporated FY2025 10-K Analysis
Business Overview
- • Core business model: Development and commercialization of specialty pharmaceuticals focusing on respiratory diseases, including key marketed products ARIKAYCE and BRINSUPRI
- • New product emphasis: BRINSUPRI launch in August 2025 generated $172.7M US sales in 2025, contributing to 66.7% overall revenue growth to $606.4M
Management Discussion & Analysis
- • Revenue not disclosed in provided text, no YoY change available
- • Profitability or margin details not provided in the excerpt
Risk Factors
- • FDA accelerated approval of ARIKAYCE contingent on successful ENCORE confirmatory trial with 425 patients enrolled as of Q4 2024
- • Exposure to inflation affecting suppliers, service providers, and partners across US, Europe, Japan, and global operations
Insmed Incorporated FY2025 Key Financial MetricsXBRL
Revenue
$606M
▲ +66.7% YoY
Net Income
-$1.3B
▼ -39.7% YoY
Operating Margin
-205.6%
▲ +3588bp YoY
Net Margin
-210.5%
▲ +4070bp YoY
ROE
-172.8%
▲ +14742bp YoY
Total Assets
$2.3B
▲ +11.8% YoY
EPS (Diluted)
$-6.42
▼ -15.3% YoY
Operating Cash Flow
-$935M
▼ -36.7% YoY
Source: XBRL data from Insmed Incorporated FY2025 10-K filing on SEC EDGAR. All figures in USD.
Get deeper insights on Insmed Incorporated
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.